Treatment Resistant Depression
Conditions
Keywords
Treatment Resistant Depression
Brief summary
Study TRD subjects' resistance to at least 2 different antidepressants, we hypothesize that because of their significant depression and treatment resistant status they are most likely to exhibit BSMN pathway abnormalities.
Detailed description
Potential subjects will be identified during clinical visits. If a patient qualifies to participate in the study they will have to stop any antidepressants that they are taking to prepare for the use of MAOIs. After a two week washout period, subjects will have an fMRI and will be started on a MAOI. They will then be followed up for 8 weeks, which is routine and considered standard care.
Interventions
DRUGMonoamine Oxidase Inhibitor (MAOI)
Monoamine Oxidase Inhibitor
Sponsors
Kathryn O'Connor
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
- TRD: 1. age: 18 - 65 yrs.; 2. satisfy criteria for DSM-IV major depressive disorder (MDD); 3. 17-item Hamilton Depression Rating Scale (17-item HDRS) score \> 18; 4. treatment resistance depression as defined as report of inadequate response (patient report of minimal improvement or nonresponse) despite past treatment with at least 2 different classes of antidepressants acting on the 5-HT and/or DA monoamine systems(except MAOIs) (as determined with the Antidepressant Treatment History Form (ATHF)20 with score of \>3 on each of the items and verified by medical records if available); 5. able to give informed consent; 6. no use of alcohol in the past 1 week and negative urine toxicology screen; 7. MAOI treatment indicated as assessed by an independent psychiatrist not affiliated with the study; 8. voluntary consent to treatment with an MAOI after reviewing all other options and agree to follow safeguards and precautions during treatment. Inclusion criteria for healthy subjects 1. ages 18-65 years and ability to give voluntary informed consent; 2. no history of psychiatric illness or substance abuse or dependence; 3. no significant family history of psychiatric or neurological illness; 4. not currently taking any prescription or centrally acting medications; no use of alcohol in the past 1 week; 5. and no serious medical or neurological illness.
Exclusion criteria
- TRD: 1. schizophrenia, schizoaffective or primary anxiety disorder; 2. serious medical or neurological illness; 3. history of significant head injury; 4. on fluoxetine treatment; 5. on lithium or have received ECT or rTMS in the last 3 months to avoid long-term effects of such medications; 6. substance or alcohol dependence in the past 6 months or substance abuse in the past 3 months; 7. unable to give informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Brainstem Structural Connectivity (Sc) | 2 years | Localize BSMN and measure pathway Sc using diffusion imaging to differentiate between TRD and HC. BSMN can be localized using diffusion imaging, and pathways projecting from BSMN to known targets can be identified. Methods have been developed to localize these nuclei via a combination of diffusion imaging and anatomic imaging. We will identify these nuclei and track their projections to known targets, giving rise to the VTA-NAcc, VTA-AMYG, RN-AM and RN-sgACC pathways. Probabilistic fiber tracking between these nodes will be used to determine a measure of pathway strength. |
| Brainstem Functional Connectivity (Fc) | 2 years | Measure BSMN pathway Fc to differentiate between TRD and HC. BSMN associated with different neuromodulators, e.g. the VTA and RN, will be associated with distinct functional networks which will be abnormal in TRD compared to HCs. |
Other
| Measure | Time frame | Description |
|---|---|---|
| 17-item Hamilton Depression Rating Scale | 2 years | Compare baseline and end of study Hamilton depression Rating scale and imaging correlations. |
Countries
United States
Outcome results
None listed